Valneva IPO Presentation Deck
Chikungunya is a Significant, Growing Public Health Concern
V
A Mosquito-Borne Viral Outbreak Disease in Tropical /Sub-tropical Regions
Can cause debilitating joint and muscle pain, fever, headache, nausea and rash,
with potential serious, long-term health impairment¹
Currently there are no vaccines or effective treatments
for chikungunya
Global market, including endemic regions (see below),
estimated to exceed $500 million annually by 2032²
2020 outbreaks³: The Americas (incl. Brazil, the
Caribbean, Colombia, Costa Rica, Mexico), Asia (India,
Malaysia, Thailand) and Africa (Congo, Kenya, Sudan)
'Valneva Chikungunya Factsheet. 2 VacZine Analytics Chikungunya virus vaccines Global demand analysis. February 2020. ECDC chikungunya worldwide overview.
Valneva - Roadshow Presentation
April 2021
17View entire presentation